Karjumin Gel is a topical dermatological formulation containing Adapalene 0.1% w/w and Clindamycin 1.0% w/w, indicated primarily for the treatment of acne vulgaris. Adapalene, a third-generation synthetic retinoid, exerts its therapeutic effect by modulating cellular differentiation, keratinization, and inflammatory processes within the pilosebaceous unit, thereby preventing the formation of comedones and promoting lesion resolution. Clindamycin, a lincosamide antibiotic, complements this action by inhibiting bacterial protein synthesis, effectively reducing Cutibacterium acnes proliferation and associated inflammation. The combination of these active ingredients provides a dual mechanism targeting both the inflammatory and non-inflammatory components of acne, enhancing overall efficacy. Karjumin Gel is typically applied once daily to the affected areas after cleansing, with caution advised to avoid contact with eyes, mucous membranes, and broken skin. Common adverse effects may include localized erythema, dryness, peeling, and mild irritation, which generally diminish with continued use. The product is contraindicated in patients with hypersensitivity to adapalene, clindamycin, or any excipients. Use during pregnancy and lactation should be under medical supervision. Karjumin Gel offers an effective therapeutic option for patients seeking combination treatment for mild to moderate acne vulgaris.